P776: ATGAM EFFICACY AND SAFETY IN MODERATE AND SEVERE ACQUIRED APLASTIC ANEMIA: OUTCOME OF A LARGE MULTICENTER COHORT OF 634 CHILDREN AND ADULTS FROM THE FRENCH AUTHORIZATION FOR TEMPORARY USE SURVEILLANCE PROGRAM
Flore Sicre de Fontbrune(Assistance Publique – Hôpitaux de Paris), Régis Peffault de Latour(Hôpital Saint-Louis), B. Valtier(Hôpital Louis-Mourier), Delphine Lebon(Centre Hospitalier Universitaire Amiens-Picardie), Fiorenza Barraco(Hôpital Lyon Sud), Thierry Leblanc(Jet Propulsion Laboratory), Yosr Hicheri(Centre National de la Recherche Scientifique), Barbara Możejko-Pastewka, Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Suzanne Tavitian(Institut universitaire du cancer de Toulouse Oncopole), Anne‐Lise Ménard(Laboratoire National Henri Becquerel), Mony Fahd(Délégation Paris 7), Sébastien Maury(Assistance Publique – Hôpitaux de Paris), Kevin D. Wolter(Pfizer (United States)), Cécile Moluçon‐Chabrot(Centre Hospitalier Universitaire de Clermont-Ferrand)
Cited by 0
Related Papers
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
|Bone Marrow Transplantation|2022|378
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
|Blood|2015|377
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
|Leukemia|2006|355
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2016|347